Literature DB >> 9036978

Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes.

M Tanaka1, T Suda, T Yatomi, N Nakamura, S Nagata.   

Abstract

Fas ligand (FasL) is a type II membrane protein. Binding of FasL to its receptor, Fas, induces apoptosis. Matrix metalloproteinase cleaves the membrane-bound human FasL to yield the active soluble form. Here, we have produced a large amount of human soluble rFasL using the yeast, Pichia pastoris. The purified rFasL was found to be glycosylated and to exist as a trimer. The rFasL was effective in inducing apoptosis in a Fas-expressing T cell or a fibroblast cell line. The ID50 of rFasL for mouse Fas-expressing T cells was about 0.5 ng/ml. The killing process with rFasL was quick. That is, >80% Fas-expressing mouse cells were killed within 1 h by a saturation concentration of human rFasL. Intravenous administration of 500 microg of human rFasL had a lethal effect in mice. When the mice were pretreated with Propionibacterium acnes, the subsequent injection of 30 microg of human rFasL induced hepatic failure and killed the mice within 24 h. These results indicated that the soluble human FasL is active in inducing apoptosis in vitro and in vivo, and its deleterious effect may be strengthened in patients who are suffering from bacterial infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9036978

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Programmed cell death and the immune system.

Authors:  Shigekazu Nagata; Masato Tanaka
Journal:  Nat Rev Immunol       Date:  2017-02-06       Impact factor: 53.106

Review 2.  Immunobiology of tumor necrosis factor receptor superfamily.

Authors:  Tong Zhou; John D Mountz; Robert P Kimberly
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Two-step engulfment of apoptotic cells.

Authors:  Satoshi Toda; Rikinari Hanayama; Shigekazu Nagata
Journal:  Mol Cell Biol       Date:  2011-10-28       Impact factor: 4.272

4.  Protection against Fas-mediated and tumor necrosis factor receptor 1-mediated liver injury by blockade of FADD without loss of nuclear factor-kappaB activation.

Authors:  K Seino; Y Setoguchi; T Ogino; N Kayagaki; H Akiba; H Nakano; H Taniguchi; Y Takada; K Yuzawa; T Todoroki; Y Fukuchi; H Yagita; K Okumura; K Fukao
Journal:  Ann Surg       Date:  2001-11       Impact factor: 12.969

Review 5.  Role of TNF superfamily ligands in innate immunity.

Authors:  Nikola L Vujanovic
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

6.  Malaria infection induces rapid elevation of the soluble Fas ligand level in serum and subsequent T lymphocytopenia: possible factors responsible for the differences in susceptibility of two species of Macaca monkeys to Plasmodium coatneyi infection.

Authors:  J Matsumoto; S Kawai; K Terao; M Kirinoki; Y Yasutomi; M Aikawa; H Matsuda
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 7.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

Review 8.  Targeting the apoptosis pathway in hematologic malignancies.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2014-02-04

9.  Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.

Authors:  J C Symes; C Siatskas; D H Fowler; J A Medin
Journal:  Cancer Gene Ther       Date:  2008-12-19       Impact factor: 5.987

10.  Intracerebroventricular injection of anti-Fas activates the hypothalamus-pituitary-adrenal axis and induces peripheral interleukin-6 and serum amyloid A in mice: comparison with other ligands of the tumor necrosis factor/nerve growth factor receptor superfamily.

Authors:  F Benigni; S Sacco; L Aloe; P Ghezzi
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.